Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

被引：0
|
作者：
Januszewski, Andrzej S.
Young, Hayden K.
Li, Liping
Oconnell, Rachel L.
Lyons, Timothy
Kelly, Clare B.
Sullivan, David
Scott, Russell
Keech, Anthony C.
Jenkins, Alicia
机构：
来源：
DIABETES | 2019年 / 68卷
基金：
英国医学研究理事会;
关键词：
D O I：
10.2337/db19-139-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
    Feng, Xiaomeng
    Gao, Xia
    Jia, Yumei
    Zhang, Heng
    Xu, Yuan
    Wang, Guang
    MEDICAL SCIENCE MONITOR, 2016, 22 : 743 - 751
  • [22] Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes
    Bhensdadia, Nishant M.
    Hunt, Kelly J.
    Lopes-Virella, Maria F.
    Tucker, J. Michael
    Mataria, Mohammad R.
    Alge, Joseph L.
    Neely, Benjamin A.
    Janech, Michael G.
    Arthur, John M.
    KIDNEY INTERNATIONAL, 2013, 83 (06) : 1136 - 1143
  • [23] Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes
    Skrha, J
    Stulc, T
    Hilgertová, J
    Weiserová, H
    Kvasnicka, J
    Ceska, R
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 493 (1-3) : 183 - 189
  • [24] Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
    Davis, Timothy M. E.
    AMERICAN JOURNAL OF CASE REPORTS, 2020, 21 : 1 - 4
  • [25] Inflammation and Oxidative Stress in Type 2 Diabetes Vascular Complications: Predictive Power and Effects of Fenofibrate in the Fenofibrate Intervention and Event Lowering in Diabetes Study
    Jenkins, Alicia J.
    Whiting, Malcolm
    Sullivan, David
    Best, James D.
    Barter, Philip
    Donoghoe, Mark
    Januszewski, Andrzej S.
    Karschimkus, Connie S.
    Blankenberg, Stefan
    Simes, John
    Scott, Russell
    Laakso, Markku
    Taskinen, Marja-Ritta
    Keech, Anthony C.
    DIABETES, 2011, 60 : A9 - A9
  • [26] Lipid Lowering, Antiinflammatory, and Vasoprotective Effects of Fenofibrate in Patients With Type 2 Diabetes Mellitus
    Tkacheva, O. N.
    Sharashkina, N. V.
    Novikova, I. M.
    Torshkhoeva, Kh. M.
    KARDIOLOGIYA, 2010, 50 (05) : 36 - 41
  • [27] Effects of Obesity, Exercise, and Type 2 Diabetes on Cardiovascular Phenotype
    Enge, Daniel
    Schafer, Michal
    Scalzo, Rebecca L.
    Rafferty, Deirdre
    Schauer, Irene E.
    Abushamat, Layla
    Whipple, Mary O.
    Johnson, Ethan
    Scott, Michael B.
    Jarvis, Kelly
    Fujiwara, Takashi
    Markl, Michael
    Hunter, Kendall S.
    Barker, Alex J.
    Nadeau, Kristen J.
    Regensteiner, Judith G.
    Reusch, Jane E.
    DIABETES, 2021, 70
  • [28] Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes
    Jenkins, Alicia J.
    OConnell, Rachel L.
    Januszewski, Andrzej S.
    Webster, Angela C.
    Davis, Timothy M. E.
    Jardine, Meg J.
    Scott, Russell S.
    Taskinen, Marja-Riitta
    Keech, Anthony C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 210
  • [29] Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial
    Warren, Rachel A.
    Carew, Allie S.
    Andreou, Pantelis
    Herman, Christine
    Levy, Andrew P.
    Ginsberg, Henry N.
    Sapp, John
    Rimm, Eric B.
    Kirkland, Susan
    Cahill, Leah E.
    DIABETES CARE, 2022, 45 (01) : 241 - 250
  • [30] Fenofibrate Reduces Peripheral Neuropathy in Type 2 Diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
    Rajamani, Kushwin
    Donoghoe, Mark
    Li, Liping
    Ting, Ru-Dee
    Colman, Peter G.
    Drury, Paul
    Laakso, Markku
    Keech, Anthony C.
    CIRCULATION, 2010, 122 (21)
12345